rosacea, rosacea-like dermatitis rosasea, rosacea-like dermatitis, erythema, telangiectasia
Conditions
Interventions
Continuous topical application of delgocitinib ointment twice a day for 12 weeks
delgositinib ointment, topical
Sponsors
Kajita Ai
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients aged 20 years or over at the time of agreement 2)Patient who have agreed by their own decision, with the written consent form, following the appropriate procedure of informed- consent. 3)Patient diagnosed as rosacea or rosacea-like dermatitis. 4)Patient that with refractory rosacea or rosacea-like dermatitis despite the standard treatments for 12 weeks or more 5)Patient without a history of delgocitinib ointment therapy
Exclusion criteria
Exclusion criteria: 1)Patient who have previously been treated with delgocitinib ointment. 2)Patients with any of the following disease to be differentiated: seborrheic dermatitis, atopic dermatitis (rosacea-like dermatitis arising in a patient with atopic dermatitis is not excluded), contact dermatitis, acne vulgaris, dermatomyositis, lupus erythematosus, drug eruption, lupus miliaris disseminatus faciei, eosinophilic pustular folliculitis, dermatomycosis and photo-allergy. 3)Miscellaneous: Patient who are considered ineligible for enrolling the study by a principal investigator or co-investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Score of clinical manifestations eight items (hot flashes, erythema, papules pustule, telangiectasia, itch, situation, drying, edema) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)presence or absence of adverse events 2) EASI score 3) NRS 4)IGA 5) Skindex-16 6)presence or absence of demodex | — |
Contacts
Public ContactAi Kajita
Okayama University Hospital
Outcome results
None listed